Swiss Biotech Stock News

Roche Holding's Ionify steroid assays for mass spectrometry have received U.S. FDA moderate complexity classification, widening access to advanced steroid hormone testing in clinical labs. Roche Pharma India has signed an MoU with NIPER Raebareli to collaborate on pharmaceutical education and research. These developments relate to both Roche's diagnostics portfolio and its global R&D footprint, including activity in India. Roche Holding (SWX:ROG) is drawing attention with regulatory...

UBS Group (SWX:UBSG) experienced a global technology outage that briefly halted parts of its trading operations. The disruption affected certain trading systems across regions before services were restored. The outage comes while UBS is integrating Credit Suisse's data and infrastructure following the recent acquisition. The incident adds to a series of similar technology disruptions reported at other large financial institutions. For you as an investor, this outage sits at the intersection...

EPIC Suisse (SWX:EPIC) issued 2026 guidance pointing to 2% to 3% net rental income growth, supported by completed developments PULSE and Campus Leman, and proposed lifting its dividend to CHF 3.20 per share. See our latest analysis for EPIC Suisse. The latest guidance and dividend proposal come after a period of steadier momentum, with a 90 day share price return of 8.39% and a 1 year total shareholder return of 20.90%, highlighting how sentiment has improved over a longer horizon. If this...

SMG Swiss Marketplace Group Holding (SWX:SMG) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 175.8 million and basic EPS of CHF 11.48, providing a clear reference point against last year’s CHF 152.2 million in revenue and CHF 8.99 EPS for the same period. The company has seen revenue move from CHF 152.2 million to CHF 175.8 million and EPS shift from CHF 8.99 to CHF 11.48 year on year for the first half. Trailing 12 month figures show EPS ranging between CHF...

Medartis Holding (SWX:MED) opened FY 2025 with first half revenue of CHF123.0 million and a basic EPS loss of CHF0.12, while trailing twelve month figures show revenue of CHF269.3 million and basic EPS of CHF0.67. Over the last few reported periods, revenue has moved from CHF111.5 million in H1 2024 to CHF113.3 million in H2 2024 and then to CHF123.0 million in H1 2025. Basic EPS shifted from CHF0.21 in H1 2024 to CHF0.09 in H2 2024 before dipping into a loss of CHF0.12 in H1 2025, putting...

TX Group (SWX:TXGN) has opened FY 2025 with first half revenue of CHF 426.6 million and EPS of CHF 0.8 loss, while the trailing twelve month figures show revenue of CHF 873.1 million and net income of CHF 36.6 million. Over recent reporting periods, revenue has ranged between CHF 461 million and CHF 480.7 million, with EPS moving from a CHF 0.9 profit to losses of CHF 1.22 and CHF 2.02. This highlights a business where headline growth expectations and actual profitability appear to be pulling...

Nestlé (SWX:NESN) is pushing harder into U.S. frozen meals and pizzas, while expanding flavored and functional coffee lines. These moves are aimed at attracting health focused and younger consumers across two of its key categories. See our latest analysis for Nestlé. Nestlé's latest push into frozen meals, pizzas and specialty coffee comes after a softer share price patch, with a 30 day share price return of 2.74% and a 1 year total shareholder return decline of 10.02% that contrasts with...

ABB Robotics (SWX:ABBN) launched its next generation AI powered RobotStudio HyperReality platform with NVIDIA, integrating Omniverse libraries for virtual to real robot deployment. The platform lets customers design, simulate, train, and optimize robots in a virtual environment with close alignment to real world performance. Early pilots with Foxconn and a demonstration with WORK show the concept applied to both large manufacturers and smaller enterprises. ABB, through its Robotics...

Sandoz Group (SWX:SDZ) has drawn investor attention after issuing CHF 550 million in dual tranche bonds and extending a US$2,000 million revolving credit facility, while reshaping its biosimilar organization under new leadership. See our latest analysis for Sandoz Group. These financing moves and the reshaping of the biosimilar unit come as Sandoz trades at CHF62.9, with a 90 day share price return of 9.51% and a 1 year total shareholder return of 69.39%. This indicates momentum building over...

Chocoladefabriken Lindt & Sprüngli (SWX:LISN) has drawn fresh attention after releasing full year 2025 results, showing higher sales, revenue and net income, and announcing an annual dividend of CHF 1,800 per share. See our latest analysis for Chocoladefabriken Lindt & Sprüngli. At a share price of CHF 112,800, Chocoladefabriken Lindt & Sprüngli has seen a 7 day share price return of 0.71%, while the 30 day share price return of an 8.14% decline contrasts with a 5 year total shareholder...

On 12 March 2026, Swiss Life Holding AG reported full-year 2025 results showing net income of CHF 1,234 million and slightly higher earnings per share, while also announcing an annual dividend of CHF 36.50 per share payable on 13 May 2026. The combination of steady profit growth and a higher cash distribution offers fresh insight into how Swiss Life balances shareholder returns with capital needs. With Swiss Life pairing higher earnings per share and an increased CHF 36.50 dividend, we’ll...

Banque Cantonale de Genève (SWX:BCGE) has put out fresh FY 2025 numbers, with first half revenue at CHF263.3 million and net income at CHF94.0 million setting the tone for how the year is shaping up. Over recent periods the bank has seen revenue move from CHF287.9 million in 1H 2024 to CHF273.8 million in 2H 2024 and then CHF263.3 million in 1H 2025, while trailing twelve month net income excluding extra items sits at CHF197.2 million against a backdrop of a 36.7% net profit margin that is...

StarragTornos Group (SWX:STGN) has just posted its FY 2025 first half results, with revenue of CHF218.2 million and a basic EPS loss of CHF1.66, while trailing twelve month figures show revenue of CHF457.3 million and a basic EPS loss of CHF0.69. Over recent reporting periods, revenue has moved from CHF254.9 million and EPS of CHF1.20 in 2024 H1 to CHF239.1 million and EPS of CHF0.97 in 2024 H2, before reaching the latest half-year levels. For investors, the focus is on how these changing...

Julius Bär Gruppe (SWX:BAER) has posted its FY 2025 results with second half revenue of CHF 1,950.2 million and basic EPS of CHF 2.28, while trailing twelve month revenue came in at CHF 3,760.4 million and EPS at CHF 3.72. Over recent periods the bank has seen revenue move from CHF 1,916.3 million in the second half of 2024 to CHF 1,810.2 million in the first half of 2025 and then to CHF 1,950.2 million in the latest half, alongside EPS shifting from CHF 2.78 to CHF 1.44 and then CHF 2.28...

u-blox Holding (SWX:UBXN) has just rolled out two GNSS products: the u-blox F11 platform and the ZED-X20D module, spotlighting its focus on low power positioning and precise heading across tracking, wearable, and industrial applications. See our latest analysis for u-blox Holding. The product launches come after a strong run in the share price, with the stock trading at CHF135.0 and a 90 day share price return of 25.46%, while the 1 year total shareholder return stands at 108.01% and the 5...

If you are wondering whether Alcon's current share price reflects its true worth, this article walks through the key numbers that matter for you as an investor. Alcon recently closed at $61.16, with returns of a 2.5% decline over 7 days, 0.3% over 30 days, a 3.7% decline year to date and a 22.2% decline over the past year, which raises questions about how the market is currently pricing the stock. Recent coverage around Alcon has focused on its position in the medical equipment space and how...

HIAG Immobilien Holding (SWX:HIAG) is back in focus after reporting full year 2025 results, with revenue of CHF 218.1 million and net income of CHF 115.1 million, alongside a higher proposed dividend. See our latest analysis for HIAG Immobilien Holding. HIAG Immobilien Holding’s recent earnings and dividend proposals have come alongside a 16.31% 90 day share price return and a 44.25% 1 year total shareholder return, suggesting positive momentum following the results. If this earnings driven...

Bachem Holding (SWX:BANB) has just wrapped up FY 2025 with second half revenue of CHF 382.1 million and basic EPS of CHF 1.31, alongside trailing twelve month revenue of CHF 695.1 million and EPS of CHF 1.98 that sit against a 23.7% earnings growth figure for the year. The company has seen revenue move from CHF 605.3 million to CHF 695.1 million on a trailing basis, while EPS has shifted from CHF 1.60 to CHF 1.98. This sets up a story of higher sales translating into improved earnings per...

Tecan Group (SWX:TECN) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 439.5 million and basic EPS of CHF 1.41. This sets the tone for how investors will read the rest of the year. The company has reported revenue of CHF 467.2 million in the first half of 2024 and CHF 467.1 million in the second half of 2024, alongside basic EPS of CHF 1.76 and CHF 3.54 respectively. This provides a clear view of how the top line and EPS have been tracking into the latest...

Wondering whether Nestlé at around CHF 80.61 is a bargain, fairly priced, or expensive? This article walks through the key clues behind the current share price. The stock has returned 0.7% over the last 7 days, 1.3% over the last 30 days, 5.5% year to date, but is still showing a 7.5% decline over 1 year, an 18.8% decline over 3 years and a 9.7% decline over 5 years. Recent headlines around Nestlé have focused on the business as a core global consumer staple, with ongoing attention on how it...

If you are wondering whether Partners Group Holding is attractively priced today, you are not alone. Many investors are trying to work out if the current share price reflects its long term potential. The stock closed at CHF 811.60, with returns of 1% decline over the last 7 days, 14.7% decline over 30 days, 21.2% decline year to date, and 35.9% decline over 1 year, while the 3 year return stands at 21.3% and the 5 year return at 15.6% decline. These moves have played out against a steady...

Earlier this month, ALSO Holding AG’s Board of Directors approved a share repurchase program of up to 9.74% of its capital for €120 million, aiming to use the treasury shares for acquisitions, liquidity, and long‑term management incentives. Around the same time, the company launched an AI Competence Center to help its partner network sell AI solutions, underscoring its focus on Microsoft 365 Copilot and the broader European AI ecosystem. We will now examine how the launch of the AI...

Amrize (SWX:AMRZ) is drawing fresh attention after launching its EVERtect high performance concrete range at CONEXPO CON/AGG, pairing this product rollout with recent insider and institutional share purchases. See our latest analysis for Amrize. Despite the EVERtect launch, insider buying and the upcoming AGM, Amrize’s recent momentum has been soft, with a 30-day share price return of a 4.62% decline and a year-to-date share price return of a 2.20% decline from CHF43.52. If this concrete...

If you are wondering whether Cosmo Pharmaceuticals at around CHF 87.00 is still offering value after a solid run, this article walks through what the current price might be implying about the company. The stock has pulled back recently, with a 19.0% decline over the last 7 days and a 24.6% decline over the last 30 days, even though the 1 year return sits at 66.3% and the 3 year return at 70.4%. These moves come against a backdrop where investors are reassessing prior gains and weighing Cosmo...